823229-34-1Relevant articles and documents
Structure-activity relationship studies of salinosporamide A (NPI-0052), a novel marine derived proteasome inhibitor
Macherla, Venkat R.,Mitchell, Scott S.,Manam, Rama Rao,Reed, Katherine A.,Chao, Ta-Hsiang,Nicholson, Benjamin,Deyanat-Yazdi, Gordafaried,Mai, Bao,Jensen, Paul R.,Fenical, William F.,Neuteboom, Saskia T. C.,Lam, Kin S.,Palladino, Michael A.,Potts, Barbara C. M.
, p. 3684 - 3687 (2005)
Salinosporamide A (1, NPI-0052) is a potent proteasome inhibitor in development for treating cancer. In this study, a series of analogues was assayed for cytotoxicity, proteasome inhibition, and inhibition of NF-κB activation. Marked reductions in potency
A METHOD OF USING PROTEASOME INHIBITORS IN COMBINATION WITH HISTONE DEACETYLASE INHIBITORS TO TREAT CANCER
-
, (2008/12/04)
Disclosed are methods of treating cancer comprising administering to the animal, a therapeutically effective amount of proteasome inhibitors and one or more histone deacetylase inhibitor. The animal is a mammal, preferably a human or a rodent.
METHODS OF USING [3.2.0] HETEROCYCLIC COMPOUNDS AND ANALOGS THEREOF FOR THE TREATMENT OF LUNG CANCER
-
Page/Page column 100, (2008/06/13)
Disclosed are methods of treating lung cancer comprising administering to the animal, a therapeutically effective amount of a heterocyclic compound, alone or in combination with another therapeutic.
